SAN FRANCISCO—The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have issued a response to a recent study that suggests patients taking semaglutide—the active ingredient in Ozempic and Wegovy—may be at higher risk of developing non-arteritic anterior ischemic optic neuropathy, or NAION, an eye condition that can cause blindness. The study, conducted by researchers at Harvard University, was published on July 3, 2024 in JAMA Ophthalmology. Read More